PD-1/PD-L1 interaction
Programmed death-1 (PD-1) is a receptor on T cells that has been shown to suppress activating signals from the T cell receptor when bound by either of its ligands, Programmed death-ligand 1 (PD-L1) or PD-L2. When PD-1 expressing T cells contact cells expressing its ligands, functional activities in response to antigenic stimuli, including proliferation, cytokine secretion, and cytotoxicity are reduced. PD-1/PD-Ligand interactions down regulate immune responses during resolution of an infection or tumor, or during the development of self tolerance.
Interference with the PD-1/PD-L1 interaction has also shown enhanced T cell activity in chronic infection systems. Chronic lymphocytic chorio meningitis virus infection of mice also exhibits improved virus clearance and restored immunity with blockade of PD-L1.
In addition to enhancing immunologic responses to chronic antigens, blockade of the PD-1/PD-L1 pathway has also been shown to enhance responses to vaccination, including therapeutic vaccination in the context of chronic infection.
Products for PD-1/PD-L1 interaction
- Cat.No. Product Name Information
-
GC50482
(D)-PPA 1
PD-1/PD-L1 interaction inhibitor
-
GC32704
Atezolizumab (MPDL3280A)
A humanized monoclonal antibody IgG1, resistant to PD-L1
-
GC31719
Avelumab (Anti-Human PD-L1, Human Antibody)
-
GC38740
BMS-1001 hydrochloride
-
GC31753
BMS-1166 (PD-1/PD-L1-IN1)
-
GC38131
BMS-1166 hydrochloride
-
GC62682
BMSpep-57 hydrochloride
-
GC62253
Camrelizumab
-
GC35913
Durvalumab
A humanized anti-PD-L1 monoclonal antibody
-
GC38044
Fraxinellone
-
GC34218
Nivolumab (BMS-936558)
Nivolumab is a programmed death-1 (PD-1) blocking antibody used to treat advanced (metastatic) non-small cell lung cancer.
-
GC36767
NP-12
-
GC36768
NP-12 (TFA)
-
GC19225
PD-1-IN-1
PD-1-IN-1 is an inhibitor of programmed cell dealth-1 (PD-1) extracted from patent WO 2015033299 A1, compound example 4.
-
GC34928
PD-1-IN-17
-
GC34929
PD-1-IN-17 TFA
-
GC63517
PD-1-IN-24
-
GC15142
PD-1/PD-L1 inhibitor 1
PD-1/PD-L1 interaction inhibitor
-
GC16762
PD-1/PD-L1 inhibitor 2
-
GC16258
PD-1/PD-L1 Inhibitor 3
PD-1/PD-L1 interaction inhibitor
-
GC62658
PD-1/PD-L1-IN 7
-
GC62125
PD-1/PD-L1-IN-10
-
GC62688
PD-1/PD-L1-IN-8
-
GC62387
PD-1/PD-L1-IN-9
-
GC62502
PD-1/PD-L1-IN-NP19
-
GC63984
PD-L1-IN-1
-
GC31878
PD1-IN-2
-
GC19531
Pembrolizumab
A IgG4-kappa monoclonal antibody against PD-1
-
GC10469
Sulfamethoxypyridazine
long-acting sulfonamide antibiotic
-
GC19131
Tomivosertib
eFT508 is a potent, highly selective, and orally bioavailable MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms.
-
GC61946
TPP-1